Clinical Trial Update: Study Evaluating ERB-041 in Active Crohn's Disease [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating ERB-041 for active Crohn's disease has completed, with sponsor Wyeth now part of Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• ERB-041

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Crohn's Disease | Phase 1 | Status: COMPLETED